LOINC Code 42065-3: Recurrence distant site 3 Cancer
42065-3 is a LOINC code used to identify Recurrence distant site 3 Cancer in laboratory and clinical observation data. You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges. LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Recurrence distant site 3. It is commonly used with the system or sample type Cancer.XXX.
What is this code?
LOINC codes identify tests, measurements, observations, survey items, and clinical questions in a standardized way. It is associated with the component Recurrence distant site 3. It is commonly used with the system or sample type Cancer.XXX.
When is it used?
- Used in lab systems, EHRs, and clinical data exchange.
- May identify a test, observation, survey item, or clinical document request rather than a diagnosis.
- Status: ACTIVE
What it does not mean
- The code identifies the observation or test, not the actual result.
Key facts
- Recurrence distant site 3 Cancer
- Recurrence distant site 3
- Code for the distant site or sites in which the tumor has recurred... NAACCR Data Standards and Data Dictionary Version 11
- CA; Identity or presence; III; Misc; Miscellaneous; Nominal; Oncology; Other; Point in time; Random; Recur distant site 3; Spec; To be specified in another part of the message; TUMOR REGISTRY(NAACCR); Unspecified
Where you may see this code
You may see this code in lab systems, lab reports, EHR exports, interoperability feeds, or other structured clinical data exchanges.
Common synonyms
Frequently asked questions
About this content
This page is prepared by HealthAssure's clinical team using official coding standards from LOINC. AI tools assist with drafting explanations, which are then reviewed and verified by healthcare professionals for accuracy. This content is for informational purposes and does not replace professional medical advice. Meet our team.